– This is an important agreement for us at IFE, as we want to be a preferred partner for the Norwegian early-stage environment in cancer research, and specifically in the field of radioactive drugs. We take on this distribution assignment with great respect for the responsibility that lies in securing cancer patients all over the world temporarily and predictably access to innovative treatment options with radioactive drugs, comments IFE Division Director Erik Flatmark, Radiopharmacy.
Radspherin® is a Radium-224 based drug that is under development and is expected to potentially treat several forms of metastatic cancer. – The agreement with IFE is an important part of our infrastructure, and allows us to offer patients to participate in the clinical trial program with access to Radspherin in a timely and predictable manner without geographical boundaries, Jan A. Alfheim, Oncoinvent’s CEO said.
Related news
-
9. June 2026
Bringing the Norwegian Battery Ecosystem Together: Highlights from the FME BATTERY Academy 2026
More than 100 participants from industry, academia and research organisations gathered in…
-
5. January 2026
From Idea to Industry: The Innovation Journey of IFE and Oliasoft
In the world of innovation, the most significant changes often begin with a simple…